Information Provided By:
Fly News Breaks for November 16, 2018
BCRX
Nov 16, 2018 | 04:58 EDT
Piper Jaffray analyst Tyler Van Buren resumed coverage of BioCryst Pharmaceuticals with an Overweight rating and $15 price target. The company has two potential $500M-plus oral drugs, both for the prophylaxis and the acute treatment of hereditary angioedema. The analyst believes both will likely be successfully developed and finds the stock undervalued at current levels.
News For BCRX From the Last 2 Days
There are no results for your query BCRX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.